Hosted on MSN
'Battling on multiple fronts': Gland Pharma shares up 5% despite subdued Q4; here's target price
Gland Pharma reported a subdued fourth quarter in FY2025, aligning with Kotak Institutional Equities' estimates but falling below consensus expectations. The company's performance was impacted by a ...
Hosted on MSN
Gland Pharma shares in focus after subsidiary Cenexi gets 11 observations from French regulator
Gland Pharma shares will be in focus on Thursday after the company announced that its material subsidiary, Cenexi, received 11 observations from France’s drug regulator, Agence nationale de sécurité ...
Gland Pharma was hit with a patent infringement lawsuit on Nov. 26 in New Jersey District Court. The action was brought by Greenberg Traurig and Rivkin Radler on behalf of Acrotech Biopharma and CyDex ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback